Objectives Increased activity of pro-inflammatory cytokines in the circulation has been observed in many, though not all, patients with congestive heart failure. To identify the predictors of cytokine activation in congestive heart failure, we assessed the relationship of peripheral and hepatic venous cytokines to central haemodynamics, neuroendocrine status and intermediary metabolism in patients with moderate or severe congestive heart failure.
Introduction
Tumour necrosis factor-a and interleukin 6 are polypeptide cytokines synthesized and released locally in response to infection and injury. The effects of tumour necrosis factor-a are mediated via receptors of 55 and 75 kD (tumour necrosis factor-receptor I and tumour necrosis factor-receptor II) the soluble forms of which also circulate in blood as a result of proteolytic cleavage from the cell surface' , and both tumour necrosis factor-a and interleukin 6, as potentially negative inotropes, are given a role in the deterioration of ventricular performance' 91 . Whether cytokines have true pathogenetic significance in congestive heart failure remains unknown.
The mechanisms responsible for increased cytokine activity in congestive heart failure are largely unknown. In the present work, we studied the relationship of peripheral venous tumour necrosis factor-a, soluble tumour necrosis factor-receptor II and interleukin 6 to characteristics of the haemodynamic and neuroendocrine state in cardiac patients with and without congestive heart failure undergoing heart catheterization. Since it has been suggested that increased right atrial pressure resulting in splanchnic congestion contributes to augmented release of cytokines in congestive heart failure 161 , we also determined hepatic venous cytokine concentrations. Our main purpose was to identify the predictors of augmented cytokine activity in congestive heart failure. Finally, since it has been suggested that cytokines contribute to the development of malnutrition in congestive heart failure, we analysed the associations between circulating cytokines and selected characteristics of the body's general energy metabolism.
Methods

Patients
The recruitment and characteristics of the study population have been published in our earlier report focusing on intermediary metabolism in congestive heart failure [10] . In short, 44 consecutive patients with congestive heart failure (28 men; mean age 56 ±13 years) and 14 patients without congestive heart failure (nine men; mean age 53 ±13 years) participated in this study. The diagnosis of congestive heart failure was based on clinical criteria' 10) . Patients with acute or chronic infectious or inflammatory diseases, recent myocardial infarction, diabetes, thyroid or other endocrine disease, hepatic, renal, gastrointestinal, connective tissue or pulmonary disease or malignancy were excluded. Also the use of drugs influencing immunoreactivity (corticosteroids, immunosuppressive agents) or intermediary metabolism (/?-adrenergic blockers) led to exclusion.
Most patients with congestive heart failure had a valvular (n=16) or ischaemic (n=9) heart disease or dilated cardiomyopathy (n=10), the rest had precapillary pulmonary hypertension (n = 5), constrictive pericarditis (n = 2) or congenital heart disease (n = 2). Eight patients were in New York Heart Association (NYHA) class IV, 20 in class HI and 16 in class II. Eleven had atrial fibrillation, five a pacemaker rhythm and 28 were in sinus rhythm. Forty-one patients were on diuretics (mean dose of furosemide, 132 mg . day"'), 34 were on digoxin, 25 used angiotensin converting enzyme inhibitors and 10 had long-acting nitrates. As antithrombotic therapy, 31 used warfarin and six low-dose aspirin. The patients without congestive heart failure had valvular (n = 8), ischaemic (n = 2) or congenital (n=4) heart disease. Eight of them were in NYHA class II and six in class I. Twelve had sinus rhythm and two atrial fibrillation. Two of them used angiotensin converting enzyme inhibitors and warfarin, three used diuretics, digoxin and nitrates and one patient was on low-dose aspirin.
Study protocol
Following a 12-h overnight fast, blood was sampled from a pre-cannulated antecubital vein for the measurement of plasma tumour necrosis factor-a, soluble tumour necrosis factor-receptor II and interleukin 6 in addition to measurement of selected neurohormones and metabolites, including noradrenaline, N-terminalproatrial natriuretic peptide (Nt-proANP), glucose, free fatty acids and ketone bodies (acetoacetate+/?-hydroxybutyrate). Cardiac catherization with sampling of blood from the hepatic vein for the determination of tumour necrosis factor-a, soluble tumour necrosis factor-receptor II and interleukin 6 was performed the same morning or within 1-2 days. A 6-min walking test was done for the assessment of exercise capacity 1 " 1 . Indirect calorimetry was performed after an overnight fast with the patient in complete supine rest for at least 30 min; the details of the technique are found elsewhere 1101 . The rates of basal metabolism and fat and carbohydrate oxidation were calculated according to previously validated formulas'
121
. The study protocol was approved by the institutional Ethics Committee and each participant gave informed consent.
Biochemical measurements
Blood samples for the determination of ketone bodies were frozen immediately and stored at -70 °C until analysed. Other blood samples were centrifuged immediately and plasma was stored at -20 °C or at -70 °C (plasma noradrenaline) until assaying. Tumour necrosis factor-a, soluble tumour necrosis factor-receptor II and interleukin 6 were determined with enzyme immunoassay kits (tumour necrosis factor-a, Medgenix Diagnostics SA, Fleurus, Belgium; soluble tumour necrosis factor-receptor II and interleukin 6, Quantikine, R&D systems, Minneapolis, MN, U.S.A.). The detection limits were 3 ng . 1 ~ ' for tumour necrosis factor-a, 5 n g . 1~' for soluble tumour necrosis factor-receptor II and 0-7 ng . 1 ~' for interleukin 6. The measurements of noradrenaline, Nt-proANP, glucose, free fatty acids and ketone bodies have been described earlier'
101
.
Echocardiography and cardiac catheterization
The cardiac ultrasound studies were made with a Toshiba SSH 140A echocardiograph and a 2-5 MHz Eur Heart J, Vol. 18, October 1997 The data are mean ± SD or median (range), *P<001, t/*<0-001 vs the control group (MannWhitney U-test). CHF = congestive heart failure; B = blood; Nt-proANP=N-terminal pro-atnal natriuretic peptide; P = plasma; S = serum.
transducer. In addition to measuring left ventricular ejection fraction' 13] , the maximal tricuspid regurgitant jet area in the right atrium was determined using colour Doppler imaging. Several apical and parasternal views were imaged and the jet areas were planimetered using the built-in software of the device. Both ejection fraction and the maximum jet area of tricuspid regurgitation were averaged over three measurements.
Pulmonary artery catheterization was performed using a balloon-tipped 7F Swan-Ganz catheter. The catheter was first introduced under fluoroscopy into the right main branch of the hepatic vein for sampling of blood for cytokine determinations. Pressure waveforms were recorded thereafter in the right atrium and pulmonary artery using a Statham P23 transducer. Cardiac output was determined according to the Fick principle' 101 .
using commercially available statistical software (Systat5.03, SYSTAT Inc., Evanston, IL, U.S.A.). Two-tailed f-values <001 were considered statistically significant.
Results
Characteristics of the study groups
Selected characteristics of the patients with and without congestive heart failure are shown in Table 1 . The data show expected differences in the haemodynamic and neuroendocrine measurements and in exercise capacity. The age and sex distribution of the study groups were comparable.
Statistical methods
The group data are summarized as mean ± SD or, in the case of asymmetrical distribution, as median and range. Peripheral and hepatic venous plasma cytokines were skewed toward high values and therefore group differences were tested with the Mann-Whitney U test.
Comparisons between peripheral and hepatic venous cytokine concentrations were made with Wilcoxon's signed rank test. Univariate associations of cytokine concentrations with the haemodynamic, neuroendocrine and metabolic measurements were analysed in the total study population by calculating Spearman's rank correlation coefficients. Multivariate predictors of plasma cytokines were determined by linear regression analysis; both dependent and explanatory variables with skewed data distribution were log transformed before analysis. All calculations were performed on a microcomputer
Peripheral and hepatic venous plasma cytokine concentrations
Plasma cytokine concentrations in peripheral and hepatic venous blood are shown in Table 2 . Peripheral venous tumour necrosis factor-a concentration was below the detection limit in one patient and interleukin 6 in three patients. Comparisons between the two groups showed that concentrations of peripheral and hepatic venous soluble tumour necrosis factor-receptor II were statistically significantly higher in patients with congestive heart failure, whereas the plasma concentrations of tumour necrosis factor-a and interleukin 6 did not differ statistically significantly between the groups (Table 2) . In congestive heart failure, plasma tumour necrosis factor-a was higher in hepatic than in peripheral venous blood (/ > <0001), but a similar trend was seen also in the absence of congestive heart failure (/ > =0074). P values from Mann-Whitney U-test. *n = 48 (36+12), tn = 54 (40+14). IL-6=interleukin-6; TNF-a = tumour necrosis factor a; sTNF-Rll = soluble tumour necrosis factor a receptor II. Other abbreviations as in Table 1 . The data are Spearman's rank correlation coefficients (r s ).
• P < 0 0 1 , t/ > <0 001. tPatients with precapillary pulmonary hypertension (n = 5) were not included in the analysis. Abbreviations as in Tables 1 and 2. Interleukin 6 concentrations in turn were lower in haemodynamic or neuroendocrine measurements. The hepatic than in peripheral venous blood in both groups, statistical associations of hepatic venous tumour necrosis factor-a, interleukin 6 and soluble tumour necrosis factor-receptor II with clinical and haemodynamic patient characteristics were similar to those found for peripheral venous cytokines (data not shown). Table 3 shows the association between peripheral venous tumour necrosis factor-a, interleukin 6 and soluble tumour necrosis factor-receptor II with clinical, haemodynamic and neuroendocrine patient characteristics in the total study population. Interleukin 6 was directly related to NYHA class ( Fig. 1) , cardiac filling pressures, Nt-proANP, and tricuspide regurgitant jet area and inversely related to systolic blood pressure, ejection fraction and exercise capacity (6 min walking distance).
Clinical, haemodynamic and neuroendocrine predictors of peripheral venous cytokine concentrations
In multivariate analysis, however, right atrial pressure was the only independent predictor of plasma interleukin 6, (P<0001) (Fig. 2) . Soluble tumour necrosis factor-receptor II was related directly to NYHA class ( Fig. 1 ) and exercise capacity but not to the other
Relationship between of nutritional and metabolic characteristics and cytokine concentrations
Body weight, body mass index and body fat mass were unrelated to peripheral or hepatic venous tumour necrosis factor-a, soluble tumour necrosis factor-receptor II and interleukin 6. The rate of basal metabolism was comparable in patients with and without congestive heart failure (78 ±13 vs 76 ± 14 J . kg~ ' . min~', /*=ns) and did not correlate with the circulating cytokine concentrations. The rates of fat and carbohydrate oxidation estimated at indirect calorimetry were also independent of cytokine concentrations (data not shown). Serum glucose, free fatty acids and blood ketone bodies were likewise unrelated to peripheral and hepatic venous tumour necrosis factor-a and soluble tumour necrosis factor-receptor II concentrations, but free fatty acids (r s =0-47, / > <0001) showed a positive correlation with peripheral venous interleukin 6. Peripheral venous tumour necrosis factor-a and soluble tumour necrosis factor-receptor II were related to the concentrations of C-peptide (r s = 0-55, /'<0001 and r s =O47, P<0001, respectively) but not with serum insulin (r s =0-35, P-m and r s = O29, P=ns).
Discussion
There is a wide variation in plasma tumour necrosis factor-a and soluble tumour necrosis factor-receptor II levels both between and within congestive heart failure patients in previous reports' 2 ' 5 ' 7 " 814 " 151 . Patients with mild to moderate congestive heart failure have often had almost normal cytokine concentrations' 6 " 7 ' 151 , and truly high concentrations have been encountered only in patients with NYHA class IV congestive heart failure. The majority of our patients had moderate congestive heart failure which may explain why their circulating cytokine concentrations were not much higher than those of patients with comparable cardiac diseases free of congestive heart failure. A recent report from the Studies of Left Ventricular Dysfunction suggested, however, that even patients with mild signs of congestive heart failure attributable to systolic dysfunction may have elevated concentrations of tumour necrosis factor-a in the circulation' 161 .
We found that plasma tumour necrosis factor-a was independent of all haemodynamic measurements, in contrast to interleukin 6 which was directly related to both left and right heart filling pressures and inversely to left ventricular function and cardiac output. Elevations of circulating tumour necrosis factor-a and interleukin 6 in congestive heart failure may therefore be attributable to different factors. Haemodynamic abnormalitiessystemic venous congestion in particular -may be important in the control of circulating interleukin 6 but the exact mechanism remains unknown.
Tumour necrosis factor-a has been incriminated in the development of malnutrition and cachexia in congestive heart failure' 2 ' 81 . However, the relationship between nutritional status and tumour necrosis factor-a has been inconsistent since not all patients with congestive heart failure and malnutrition have had increased circulating tumour necrosis factor-a concentrations. Although a high prevalence of impaired nutrition has been reported in chronic congestive heart failure' 171 , only one of our patients had malnutrition by the criteria Eur Heart J, Vol. 18. October 1997 . The rarity of malnutrition may explain why the concentrations of tumour necrosis factor-a and soluble tumour necrosis factor-receptor II were not markedly elevated in our patients with NYHA IV class symptoms and why we did not find clear associations between the bodily measurements and circulating cytokines.
Recently, it has been suggested that tumour necrosis factor-a is a link between obesity and insulin resistance in diabetes' 181 . Interestingly, our patients had a relatively strong positive correlation between serum C-peptide and plasma tumour necrosis factor-a. In some studies, congestive heart failure has also been found to be an insulin resistant state, but the underlying mechanisms are not well understood 119 " 201 . However, plasma tumour necrosis factor-a did not predict the rates of basal metabolism and substrate oxidation or the concentrations of circulating metabolites. The association of serum free fatty acids with plasma interleukin 6 probably reflects the fact that both interleukin 6 and the metabolites correlate directly with the filling pressures of the heart 1101 .
Certain limitations of our data should be recognized. First, blood samples for peripheral and hepatic venous cytokine determinations were not collected simultaneously, even though the majority were taken during the same morning and all within 1 to 2 days. Therefore, comparisons between peripheral and hepatic venous correlations should be made with caution. Second, the cytokines, their natural antagonists and binding proteins build up a complex network and we acknowledge that a number of additional mediators may regulate the biological effects of cytokines, which were not measured in this study.
In conclusion, the present data in cardiac patients suggest that plasma concentrations of tumour necrosis factor-a and soluble tumour necrosis factorreceptor II were related to symptoms and exercise tolerance, while interleukin 6 concentration was associated with a number of haemodynamic and neuroendocrine measurements. High systemic venous pressure was the single most important predictor of elevated circulating interleukin 6. In patients with congestive heart failure free of detectable malnutrition, bodily measurements and the rates of basal metabolism and substrate oxidation were not related to plasma tumour necrosis factor-a levels. The splanchnic area may modify the plasma cytokine concentrations.
